



**Northwest Biotherapeutics, Inc**  
("NWBT" or the "Company")

**Financial Results for the First Quarter  
Period Ended 31 March 2008**

BETHESDA, MD – 16 May 2008 – Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC BB: NWBO), today announced its results for the first quarter period ended 31 March 2008 as set forth below and in the attached Form 10-Q as filed with the SEC on 15 May 2008. A link to this document is [LONDON STOCK EXCHANGE to insert link].

**For further information, please contact:**

**Northwest Biotherapeutics, Inc**

Anthony P. Deasey, Chief Financial Officer

+1 240-497-9024

**Buchanan Communications**

Lisa Baderoon (lisab@buchanan.uk.com) / Mary-Jane Johnson / Catherine Breen

+44 (0)20 7466 5000

**Collins Stewart Europe Limited**

Tim Mickley / Adam Cowen

+44 (0)20 7523 8350

## About NWBT

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, with limited toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax<sup>®</sup> for recurrent ovarian cancer. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at [www.nwbio.com](http://www.nwbio.com).

## Disclaimer

*Statements made in this news release that are not historical facts, including statements concerning the Company's plans to move its programs forward, statements regarding the Company's clinical trials and other business development activities, and statements regarding its fundraising activities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks and uncertainties regarding the Company's ability to secure additional financing or raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings, including in the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and in its recently filed Form S-1. Finally, there may be other factors not mentioned above or included in the Company's SEC filings or recently filed Form S-1 that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.*

**NORTHWEST BIOTHERAPEUTICS, INC**  
(A Development Stage Company)

**Condensed Consolidated Statement of Operations**  
(in thousands, except for per share data)

**Three Months ended  
March 31  
(Unaudited)**

	\$	2007	\$	2008
Revenues				
Operating expenses				
Research and development		1,311		3,062
General and administrative		511		2,625
Total operating expenses		1,822		5,687
Loss from operations		(1,822)		(5,687)
Other income (expense)				
Interest income		131		12
Interest expense		1		74
Net income (loss)		(1,952)		(5,625)
Net income (loss) loss applicable to common stockholders		(1,952)		(5,625)
Net income (loss) per common share - basic and diluted		(0.45)		(0.13)
Weighted average shares outstanding - basic and diluted		4,349		42,346

**NORTHWEST BIOTHERAPEUTICS, INC**  
(A Development Stage Company)

**Condensed Consolidated Balance Sheet**  
(in thousands, except for per share data)

	<b>December 31 2007</b>	<b>March 31 2008 (Unaudited)</b>
<b>Current assets</b>		
Cash and short term investments	\$ 7,861	\$ 2,578
Prepaid and other current assets	823	795
<b>Total current assets</b>	<b>8,684</b>	<b>3,373</b>
Property and equipment, net	19	124
Deposit and other non-current assets	3	2
<b>Total other assets</b>	<b>22</b>	<b>126</b>
<b>Total assets</b>	<b>8,706</b>	<b>3,499</b>
<b>Current liabilities</b>		
Accounts payable	1,007	1,094
Accrued expenses	1,892	1,173
<b>Total current liabilities</b>	<b>2,899</b>	<b>2,267</b>
<b>Total liabilities</b>	<b>2,899</b>	<b>2,267</b>
<b>Stockholders' equity/(deficit)</b>		
Common stock	42	42
Additional paid-in capital	148,064	149,160
Accumulated deficit	(142,299)	(147,970)
<b>Total stockholders' equity / (deficit)</b>	<b>5,807</b>	<b>1,232</b>
<b>Total liabilities and stockholders' equity / (deficit)</b>	<b>8,706</b>	<b>3,499</b>